Myeloprotection following cytotoxic damage: the sooner the better.
Hérodin
Francis
F
Drouet
Michel
M
D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D001854:Bone Marrow Cells / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D003114:Colony-Forming Units Assay; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004353:Drug Evaluation, Preclinical; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000191:economics / Q000627:therapeutic use; D006098:Granulocytes / Q000187:drug effects; D019650:Hematopoietic Stem Cell Mobilization; D007958:Leukocyte Count; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D038042:Myelopoiesis / Q000187:drug effects; D009503:Neutropenia / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D010976:Platelet Count; D019707:Receptors, Chemokine / Q000378:metabolism; D011994:Recombinant Proteins; D013047:Specific Pathogen-Free Organisms
D018952:Antigens, CD34; C503133:Gr-1 protein, mouse; D019653:Myeloablative Agonists; D019707:Receptors, Chemokine; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide